Drug "SPL"

That it has developed a drug that prevents the function of a gene crucial to cancer cells to divide and proliferate , research team of RIKEN and the Cancer Research Society has announced the U.S. magazine cancer oncogene electronic version . Where were transplanted into mice human cancer cells were allowed to drink the drug , it was possible only suppress cancer cells to divide and proliferate . It may become a new anti-cancer agents.Division actively than normal cells , cancer cells to proliferate . When cells divide , needing chromosome DNA gathered is duplicated and is distributed equally into two .Yao senior researcher from the Cancer Research Committee , gene of interest to separate the control this chromosome that the replicated " microtubule " and " TACC3 " . Interference with the action of this gene , it was found that the arrangement of microtubules is disrupted , cell division stops.We have developed drug " SPL " to improve so as to find a promising drug candidate from among the compounds of type 6800 , the work density even at low .
I want you to aim for practical use to promote research as soon as possible to clinical trials .


がん細胞が分裂・増殖するのに不可欠な遺伝子の働きを妨げる薬剤を開発したと、がん研究会と理化学研究所の研究チームが米がん専門誌オンコジーン電子版に発表した。ヒトのがん細胞をマウスに移植し、この薬剤を飲ませたところ、がん細胞だけ分裂・増殖を抑えることができた。新たな抗がん剤になる可能性があるという。
　がん細胞は正常な細胞より盛んに分裂、増殖する。細胞が分裂する際には、DNAが集まった染色体が複製され、二つに均等に分配される必要がある。
　がん研究会の八尾主任研究員らは、この複製された染色体を引き離す「微小管」を制御する遺伝子「TACC3」に注目。この遺伝子の働きを妨げると、微小管の配置が乱れ、細胞分裂が止まることが分かった。
　6800種類の化合物の中から有力な薬剤候補を探し出し、濃度が低くても効くよう改良して薬剤「SPL」を開発した。　
　臨床実験まで速やかに研究を進めて実用化を目指して欲しいですね。